Definium chalks up new phase 3 win for LSD-based therapy
Psychedelic drug developer Definium Therapeutics has reported positive phase 3 results with its LSD-based therapy DT120.
Definium Therapeutics
Clinical-stage psychedelics company developing LSD-based therapies for major depressive disorder and other psychiatric conditions.
Company Info
Sector:Psychedelics & Related
Headquarters:San Diego, California, USA
Founded:2020
Website:definiumtx.com/
Upcoming Milestones & Key Dates
2026 H2
Clinical readout
Phase 3 topline data (DT-120 MDD)
2027 H1
Regulatory filing
NDA submission for DT-120
Clinical Development Pipeline
DT-120
Target: 5-HT2A agonist (LSD)DT-220
Target: 5-HT2A agonistDT-310
Target: 5-HT2A agonistRecent News
Definium hits another ph. 3 homerun with anxiety ‘sea change’
Definium hits another ph. 3 homerun with anxiety ‘sea change’
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts
Psychedelics surge again as Compass, Definium provide more clinical validation
BioSpace reports: Psychedelics surge again as Compass, Definium provide more clinical validation.
Definium's LSD-based therapy elicits 'profound' efficacy in Phase 3 depression trial
Definium Therapeutics reported Phase 3 results showing its LSD-based therapy elicited 'profound' efficacy in treatment-resistant depression, marking a notable psychedelic-pharma readout.
Definium reports Phase 3 hit for LSD drug in severe depression
Definium Therapeutics' LSD-based therapy showed 'profound' efficacy in a late-stage trial in major depressive disorder.
Leadership Team
Robert Barrow
Chief Executive Officer